Digital Content 
NEWS #PharmaBuzz
27 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250427143523/en/OLYMPUS-Long-Term-Follow-Up-Study-Reports-Nearly-Four-Year-Duration-of-Response-in-Subset-of-Patients-with-Low-Grade-Upper-Tract-Urothelial-Cancer-Who-Achieved-a-Complete-Response-to-Initial-JELMYTO-Treatment
27 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250427131895/en/New-Patient-Reported-Outcomes-from-UGN-102-Clinical-Trials-Show-the-Investigational-Treatment-Did-Not-Adversely-Affect-Functionality-Symptom-Burden-and-Quality-of-Life-in-Patients-with-LG-IR-NMIBC
27 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250427607639/en/New-Long-Term-Follow-Up-Data-from-OPTIMA-II-Study-of-UGN-102-Demonstrates-Median-Duration-of-Response-of-Two-Years-in-Patients-with-LG-IR-NMIBC
26 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250426951270/en/UroGen-Announces-Updated-18-Month-Duration-of-Response-DOR-of-80.6-from-the-Phase-3-ENVISION-Trial-of-UGN-102-an-Investigational-Treatment-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC
28 Oct 2024
// BUSINESSWIRE
15 Oct 2024
// BUSINESSWIRE
Share 